If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Found under the patio at Cromwell Street was the body of the Wests' daughter, Heather, who had been murdered in June 1987 after being abused by her parents all her life. It is said that Heather had begun to tell her friends about her abuse. Barry, her younger brother, would later describe watching, as a seven-year-old, his mother kick Heather repeatedly about the head until she was no longer moving. The Wests had told friends and concerned parties that Heather left home to work at a Devonshire holiday village and on one occasion fabricated a phone call, supposedly from Heather, to allay her siblings' suspicions about her disappearance. Fred would even taunt his children when they misbehaved by jokingly stating, "If you don't behave, you'll end up under the patio like Heather." This was the last known murder that the pair committed. While on remand at HM Prison Birmingham, Fred died by suicide by hanging on 1 January 1995.
== See also == Ki Database Ion channel linked receptors Neuropsychopharmacology Schild regression for ligand receptor inhibition Signal transduction Stem cell marker List of MeSH codes (D12.776) Receptor theory
== Uses == α-Arbutin is used in the cosmetic and pharmaceutical industries for its skin lightening effects, treatment of hyperpigmentation, and as a possibly safer alternative to hydroquinone. It may also possess antioxidant properties, which can protect the skin from free radical damage. It is used in products aimed at fading solar lentigo, freckles, melasma, and other forms of hyperpigmentation where excess melanin is a concern, providing a more even skin complexion. For this purpose, concentrations of up to 2% α-arbutin are found in face creams and serums and 0.5% in body creams. α-Arbutin showed a significant reduction in melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model, with melanin synthesis reduced to 40% of the control, indicating its potency as a skin lightening agent without affecting cell viability.
Sources: en.wikipedia.org
=== Patents === U.S. Patent No. 8871759 was published in 2014 for the specified compounds useful for hepatitis C virus NS5A inhibitors. The patent protects Merck's formulation for the drug and its other associated salt forms, hydrates, solvates, prodrugs and isomers. U.S. Patent No. 7973040 was published in 2011. The patent protects the invention by Merck of the macrocyclic compound within the formula as an inhibitor for NS3 protease. The patent describes the formulation of the compound and its salts, along with its uses and potential implications as an HCV antiviral treatment.
=== Sex assignment and sexuality === Most individuals with CAIS are raised as females. They are born with an external phenotype of a typical female and are thought to be usually heterosexual with a female gender identity; however, some research has suggested that individuals with CAIS are more likely to have more variable gender outcomes and a non-primarily heterosexual sexual orientation than relatively similar control groups of those with MRKH syndrome and PCOS, contradicting this belief. At least two case studies have reported male gender identity in individuals with CAIS. A possible explanation is that sex chromosomes may directly affect neural system regardless of levels of gonadal steroids. A study observed a mixture of "male" and "female" neuronal coding in CAIS individuals.
Size-exclusion chromatography (SEC) is also known as gel permeation chromatography (GPC) or gel filtration chromatography and separates molecules according to their size (or more accurately according to their hydrodynamic diameter or hydrodynamic volume). Smaller molecules are able to enter the pores of the media and, therefore, molecules are trapped and removed from the flow of the mobile phase. The average residence time in the pores depends upon the effective size of the analyte molecules. However, molecules that are larger than the average pore size of the packing are excluded and thus suffer essentially no retention; such species are the first to be eluted. It is generally a low-resolution chromatography technique and thus it is often reserved for the final, "polishing" step of a purification. It is also useful for determining the tertiary structure and quaternary structure of purified proteins, especially since it can be carried out under native solution conditions.
Sources: en.wikipedia.org
Daisy was the most famous campaign commercial of the Cold War. Aired only once, on 7 September 1964, it was a factor in Lyndon B. Johnson's defeat of Barry Goldwater in the 1964 presidential election. The contents of the commercial were controversial, and their emotional impact was searing. The commercial opens with a very young girl standing in a meadow with chirping birds, slowly counting the petals of a daisy as she picks them one by one. Her sweet innocence, along with mistakes in her counting, endear her to the viewer. When she reaches "9", an ominous-sounding male voice is suddenly heard intoning the countdown of a rocket launch. As the girl's eyes turn toward something she sees in the sky, the camera zooms in until one of her pupils fills the screen, blacking it out. The countdown reaches zero, and the blackness is instantly replaced by a simultaneous bright flash and thunderous sound which is then followed by footage of a nuclear explosion, an explosion similar in appearance to the near surface burst Trinity test of 1945, followed by another cut to footage of a billowing mushroom cloud. As the fireball ascends, an edit cut is made, this time to a close-up section of incandescence in the mushroom cloud, over which a voiceover from Johnson is played, which states emphatically, "These are the stakes! To make a world in which all of God's children can live, or to go into the dark. We must either love each other, or we must die." Another voiceover then says, "Vote for President Johnson on November 3.
On October 31, a federal judge in Rhode Island cited the Administrative Procedure Act and temporarily ordered the Trump administration to continue SNAP funding. A second federal judge in Boston said the Trump administration's plan to stop SNAP funding during the shutdown was against the law, but did not order payments to resume. On November 7, Justice Ketanji Brown Jackson temporarily froze the lower court order requiring full payment of SNAP. ABC News stated, "at least nine states had already begun issuing SNAP benefits under the direction of the federal agency that operates SNAP," reportedly including California, Wisconsin, Kansas, Pennsylvania, New York, New Jersey, and Vermont. In early November, Trump called for ending the Senate's rule and tradition of the filibuster. On November 6, some Republican senators talked about making a "clean" Continuing Resolution one of the exceptions to the filibuster rule, but it's estimated that this change is unlikely. On November 9, the Senate achieved a 60-vote compromise of a "mini-bus" which will fund certain departments through next September and the rest of government through January 30. SNAP would be funded through September 2026. Senate Republicans agreed to have a vote on the Obamacare funding by the 2nd week of December. Eight Democrats voted with Republicans to end the shutdown. On November 12, the House passed the bill, 222 to 209. Trump then signed it into law.
=== Gynecomastia === Flutamide, as a monotherapy, causes gynecomastia in 30 to 79% of men, and also produces breast tenderness. However, more than 90% of cases of gynecomastia with NSAAs including flutamide are mild to moderate. Tamoxifen, a selective estrogen receptor modulator (SERM) with predominantly antiestrogenic actions, can counteract flutamide-induced gynecomastia and breast pain in men.
==== Inner city development ==== Heseltine faced initial suspicion from Labour-led Merseyside Council, but got on well with Sir Trevor Jones, Liberal leader of Liverpool City Council. Jones, also a self-made businessman, got on well with Heseltine, and Jones claimed that Heseltine admitted to him late one night that he was a Liberal at heart, but could not bear the thought of having no realistic chance to win power. Inspired by the Bundesgartenschauen which had helped to regenerate German cities after the war, Heseltine arranged for the first of five biennial National garden festivals to be held in Liverpool in 1984 (Jones arranged for the council to delegate the bid to the Merseyside Development Corporation, of which he was a director). More than 3 million people eventually attended. Heseltine arranged for Liverpool to receive unused government grants for other cities (from the Urban Programme), although the money was less than had been clawed back from Liverpool through council spending cuts. He also played an important role in the redevelopment of Albert Dock, the development of Wavertree Technology Park (the land purchased by £10 million of public money) and the development of Cantril Farm estate into Stockbridge Village, arranging for Barratt Developments to build many new houses for owner occupiers. Heseltine also played an important role in the development of Urban Development Corporations, directly appointed by the minister and overriding local authority planning controls to spend government money on infrastructure.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.